Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,590JPY
26 Aug 2016
Change (% chg)

¥-30 (-1.82%)
Prev Close
¥1,620
Open
¥1,620
Day's High
¥1,620
Day's Low
¥1,560
Volume
7,951,600
Avg. Vol
8,083,247
52-wk High
¥1,837
52-wk Low
¥1,358

Latest Key Developments (Source: Significant Developments)

Astellas Pharma to create companion diagnostic for acute Myeloid Leukemia treatment-Nikkei<4503.T>
Monday, 15 Aug 2016 03:39pm EDT 

Nikkei: Astellas Pharma to create with U.S. co so-called companion diagnostic for acute myeloid leukemia treatment the co has been working on-Nikkei . Astellas Pharma seeks to obtain approval in Japan, U.S. and elsewhere within three years-Nikkei .  Full Article

Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan
Tuesday, 9 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder .Says it has a license agreement with AstraZeneca UK Ltd. that provides the co exclusive rights to develop and commercialize extended-release tablets of quetiapine fumarate in Japan.  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 10:57am EDT 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

DigiTx Partners says raised about $10.5 mln in equity financing
Thursday, 4 Aug 2016 12:35pm EDT 

Digitx Partners Llc : Digitx Partners LLC says it raised about $10.5 mln in equity financing of the total offering amount of $21 mln - SEC .  Full Article

Astellas Pharma unit to sell Astellas Pharma Technologies to Avara
Thursday, 4 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time) .Says transaction price is not disclosed.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara
Wednesday, 3 Aug 2016 08:52pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara<4503.T>
Wednesday, 3 Aug 2016 07:00pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

Cytokinetics, Astellas announce option right for Tirasemtiv
Wednesday, 27 Jul 2016 07:30am EDT 

Cytokinetics Inc : Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS . Option has potential for more than $100 million in payments associated with exercise of option . To receive $65 million in upfront payments, $30 million in additional sponsored research and development .Companies to extend joint research focused on discovery of skeletal muscle activators through 2017.  Full Article

Shionogi and Astellas Pharma looking to sell drug brands that have lost patent protection - Nikkei<4503.T><4507.T>
Monday, 4 Jul 2016 04:34pm EDT 

Nikkei: Shionogi and Astellas Pharma are looking to sell off drug brands that have lost patent protection - Nikkei . Shionogi could select buyers at the end of July; proceeds from the sales estimated at nearly 20 billion yen - Nikkei . Astellas could receive up to 50 billion yen by divesting several drugs - Nikkei .  Full Article

Medivation and Astellas initiate Phase III trial of enzalutamide
Thursday, 2 Jun 2016 07:00am EDT 

Medivation Inc : Astellas and Medivation initiate Phase III trial of enzalutamide in patients with triple-negative breast cancer .Trial, which will be led by Medivation, is expected to begin patient enrollment in Q4 of 2016.  Full Article

Photo

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video